<DOC>
	<DOCNO>NCT01519791</DOCNO>
	<brief_summary>This study intend evaluate efficacy safety Certolizumab Pegol ( CZP ) combination Methotrexate ( MTX ) induce sustain clinical response treatment Disease Modifying Antirheumatic Drug ( DMARD ) -na誰ve adult early active Rheumatoid Arthritis .</brief_summary>
	<brief_title>A Multi-center , Randomized , Double-blind , Placebo-controlled Study Evaluate Efficacy Safety Certolizumab Pegol Combination With Methotrexate Treatment Disease Modifying Antirheumatic Drugs ( DMARD ) -na誰ve Adults With Early Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>Subjects must time since diagnosis adultonset Rheumatoid Arthritis ( RA ) less 1 year define 2010 ACR/EULAR classification criterion Screening Visit Positive Rheumatoid Factor ( RF ) and/or positive anticyclic Citrullinated Peptide Antibody ( antiCCP ) Active RA disease DMARDna誰ve Subject na誰ve RA relate biologics A diagnosis inflammatory Arthritis History infect joint prosthesis , significant infection serious medical condition Known Tuberculosis ( TB ) disease high risk acquire TB infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Certolizumab Pegol - Cimzia</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>